Why Pfizer Stock Still Looks Deeply Undervalued In 2026

May 18, 2026 09:28:12 am

Source: SeekingAlpha

2026-05-18 09:28:12 ET

In my March article, "Why Pfizer Remains A Strong Buy In 2026" , I mainly discussed Pfizer's Q4 earnings ( PFE ) and the efficacy of Ibrance's successor, called atirmociclib, in the Phase 2 FOURLIGHT-1 study ....

For further details see:

Sanofi

0.41% G/L:

$42.67 Last:

1,105,239 Volume:

$42.56 Open:

June 03, 2026 09:13:54 am

May 18, 2026 04:50:00 pm

May 06, 2026 12:42:00 pm

May 04, 2026 01:00:00 pm

Market Cap $119,804,457,217

Float 2,430,957,423

Insiders Ownership N/A

Institutions 389

Short Percent N/A

Industry Pharmaceuticals

Sector Healthcare

Country FR

City Paris